U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06819514) titled 'The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease' on Jan. 22.
Brief Summary: A phase 1/2, multicenter, open-label, Dose-escalation study to evaluate the safety and efficacy of intravenous EXG110 in patients with Fabry disease
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Fabry Disease
Intervention:
DRUG: EXG110 Injection
EXG110 Injection is gene therapy for Fabry Disease , uses a proprietary AAV capsid with improved liver and muscle specificity.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hangzhou Jiayin Biotech Ltd
Disclaimer: Curated by HT Syndication....